Non-hodgkin Lymphomas (NHL) are a heterogenous group of B-cell and T-cell malignancies arising from the lymphoid tissue with varied features.

 

NHL is divided according to cell lineage, the development stage of the lymphocytes and clinical features. The majority arise from B lymphocytes with the most common types of NHL being diffuse large B-cell lymphoma and follicular lymphoma. Other types include Marginal zone B-cell, peripheral T-cell, mantle cell and NK-cell lymphoma. Chronic lymphocytic leukemia is also recognised as a type of NHL.

NHL incidence is slightly higher in men. There are a diverse range of risk factors that increase vulnerability to NHL including viruses such as HIV, autoimmune disease, immunosuppressants, smoking and pesticides. Although treatment is dependent on the type of lymphoma, the R-CHOP regimen is commonly used for NHLs. Clinical outcomes in B-cell lymphomas have significantly improved over the past decade due to rituximab.

View Lymphoma Overview Page

Non-Hodgkin Lymphoma

The Lymphoma Channel on VJHemOnc is supported by Takeda and Karyopharm Therapeutics. The companies have no influence over the production of the content.

Non-Hodgkin Lymphoma

Non-hodgkin Lymphomas (NHL) are a heterogenous group of B-cell and T-cell malignancies arising from the lymphoid tissue with varied features.

 

NHL is divided according to cell lineage, the development stage of the lymphocytes and clinical features. The majority arise from B lymphocytes with the most common types of NHL being diffuse large B-cell lymphoma and follicular lymphoma. Other types include Marginal zone B-cell, peripheral T-cell, mantle cell and NK-cell lymphoma. Chronic lymphocytic leukemia is also recognised as a type of NHL.

NHL incidence is slightly higher in men. There are a diverse range of risk factors that increase vulnerability to NHL including viruses such as HIV, autoimmune disease, immunosuppressants, smoking and pesticides. Although treatment is dependent on the type of lymphoma, the R-CHOP regimen is commonly used for NHLs. Clinical outcomes in B-cell lymphomas have significantly improved over the past decade due to rituximab.

The Lymphoma Channel on VJHemOnc is supported by Takeda and Karyopharm Therapeutics. The companies have no influence over the production of the content.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter